Table 1 Outcomes among pediatric patients treated with blinatumomab 5/15 µg/m²/day

From: Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Outcome subject	Age [years]	Disease status^a: prior alloHSCT/# relapses/refractory	Outcomes and other treatments after blinatumomab
Outcome subject	Age [years]	Disease status^a: prior alloHSCT/# relapses/refractory	CR/MRD response	CD19-negative	AlloHSCT	CAR T-cells	Disposition	Survival [months]
Alive at last follow-up (survivors at 24 months)
1	1	Yes/-/No	Yes/Yes		Yes		Alive	24.0
2	1	Yes/-/No	Yes/Yes		Yes		Alive	24.3
3	14	Yes/-/Yes	Yes/Yes				Alive	23.6
4	13	Yes/-/No	Yes/No				Alive	24.4
5	17	No/2 + /No	Yes/No		Yes		Alive	24.1
6	1	Yes/-/No	Yes/No			Yes	Alive	22.8
7	11	Yes/-/No	No/No		Yes		Alive	24.4
8	9	Yes/-/No	No/No		Yes		Alive	24.1
9	17	Yes/-/No	No/No		Yes		Alive	23.7
10	12	No/1/Yes	No/No		Yes		Alive	23.5
11	5	Yes/-/Yes	No/No				Alive	24.3
12	17	Yes/-/No	No/No		Yes	Yes	Alive	23.8
13	< 1	No/0/Yes	No/No	Yes	Yes		Alive	23.7
14	17	No/2 + /No	No/No		Yes	Yes	Alive	23.8
Discontinued study early, alive at time of discontinuation
15	6	No/2 + /No	Yes/Yes	Yes	Yes		Alive: Subject withdrew	10.9^b
16	14	Yes/-/No	Yes/Yes				Alive: Subject withdrew	9.9^b
17	9	Yes/-/Yes	Yes/No				Alive: Subject withdrew	1.8^b
18	1	No/1/Yes	No/Yes				Alive: Subject withdrew	0.5^b
19	5	No/1/Yes	No/NA				Alive: Subject withdrew	0.4^b
20	5	Yes/-/No	No/No		Yes		Alive: Lost to follow-up	12.0^b
21	7	Yes/-/No	No/No				Alive: Physician decision	0.5^b
22	9	No/1/Yes	No/No				Alive: Subject withdrew	0.9^b
Died while in continuous hematological CR after blinatumomab
23	1	No/2 + /Yes	Yes/Yes		Yes		Died: multiorgan failure	3.1
24	10	Yes/-/Yes	Yes/Yes	NA	Yes		Died: fatal septic shock	12.5
25	16	Yes/-/Yes	Yes/Yes		Yes		Died: renal failure	14.6
Achieved hematological CR and relapsed before death
26	2	Yes/-/No	Yes/Yes	NA			Died	4.9
27	5	No/1/Yes	Yes/Yes	Yes^c			Died	10.4
28	8	Yes/-/No	Yes/Yes		Yes		Died	19.4
29	8	Yes/-/No	Yes/Yes	NA			Died	15.0
30	7	Yes/-/Yes	Yes/Yes		Yes		Died	17.3
31	12	Yes/-/Yes	Yes/Yes		Yes		Died	3.2
32	6	No/1/Yes	Yes/Yes		Yes		Died	6.5
33	3	No/2 + /Yes	Yes/NA		Yes	Yes	Died	8.1
34	11	Yes/-/No	Yes/No				Died	6.5
35	10	Yes/-/No	Yes/No				Died	9.3
36	1	Yes/-/No	Yes/No				Died	1.7
37	16	Yes/-/No	Yes/No			Yes^d	Died	3.6
38	1	Yes/-/No	Yes/No				Died	3.7
39	6	No/1/Yes	Yes/No				Died	5.2
40	4	No/1/Yes	Yes/No		Yes	Yes	Died	11.2
Never responded to blinatumomab before death
41	7	Yes/-/No	No/NA				Died	0.2
42	11	No/1/Yes	No/NA				Died	0.8
43	13	No/1/Yes	No/NA				Died	0.5
44	6	No/1/Yes	No/NA		Yes		Died	2.7
45	14	Yes/-/No	No/NA				Died	0.7
46	3	Yes/-/Yes	No/NA				Died	0.8
47	12	Yes/-/No	No/No				Died	1.7
48	5	No/0/Yes	No/No				Died	2.9
49	3	No/1/Yes	No/No				Died	4.3
50	9	No/1/Yes	No/No				Died	4.0
51	13	No/2 + /Yes	No/No		Yes		Died	12.4
52	14	No/1/Yes	No/No				Died	2.8
53	< 1	No/1/Yes	No/No	Yes			Died	1.1
54	17	Yes/-/No	No/No		Yes		Died	8.2
55	4	Yes/-/Yes	No/No				Died	4.2
56	5	Yes/-/No	No/No				Died	11.8
57	12	Yes/-/Yes	No/No				Died	1.4
58	8	Yes/-/Yes	No/No				Died	2.4
59	16	Yes/-/No	No/No				Died	1.4
60	9	No/1/Yes	No/No				Died	1.6
61	11	Yes/-/No	No/No				Died	10.6
62	6	No/1/Yes	No/No		Yes		Died	15.8
63	10	No/2 + /Yes	No/No				Died	3.8
64	6	No/2 + /No	No/No				Died	3.7
65	6	No/1/Yes	No/No				Died	3.5
66	< 1	No/1/Yes	No/No				Died	2.3
67	13	Yes/-/Yes	No/No			Yes	Died	7.5
68	11	No/1/Yes	No/No				Died	5.7
69	10	Yes/-/Yes	No/No				Died	1.6
70	8	Yes/-/No	No/No				Died	9.6

alloHSCT allogeneic hematopoietic stem cell transplantation, CR complete remission, MRD minimal residual disease, NA not analyzed, OS overall survival
^aBased on reason for study inclusion; number of prior relapses was not reported for patients with prior alloHSCT, who could enroll regardless of prior relapses or refractory disease
^bOverall survival was censored at the time of early study discontinuation
^cFor this patient, CD19-negativity occurred for the second relapse after blinatumomab treatment
^dThis patient received CAR T-cells before blinatumomab treatment; all other reported CAR T-cell administrations occurred after blinatumomab treatment

Back to article page

Table 1 Outcomes among pediatric patients treated with blinatumomab 5/15 µg/m²/day

Search

Quick links